within Pharmacolibrary.Drugs.ATC.A;

model A02BX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.005,
    Cl             = 0.0025,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.00023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bismuth subcitrate is an inorganic compound used primarily for the treatment of peptic ulcers, gastritis, and to eradicate Helicobacter pylori infection, often in combination regimens. It acts locally in the gastrointestinal tract and is approved for clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult volunteers after oral administration, as published data on bioavailability and systemic PK after oral intake are sparse due to minimal systemic absorption.</p><h4>References</h4><ol><li><p>Benet, LZ (1991). Safety and pharmacokinetics: colloidal bismuth subcitrate. <i>Scandinavian journal of gastroenterology. Supplement</i> 185 29–35. DOI:<a href=&quot;https://doi.org/10.3109/00365529109093217&quot;>10.3109/00365529109093217</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1957122/&quot;>https://pubmed.ncbi.nlm.nih.gov/1957122</a></p></li><li><p>Canena, J, et al., &amp; Quina, MG (1998). Distribution of bismuth in the rat after oral dosing with ranitidine bismuth citrate and bismuth subcitrate. <i>The Journal of pharmacy and pharmacology</i> 50(3) 279–283. DOI:<a href=&quot;https://doi.org/10.1111/j.2042-7158.1998.tb06861.x&quot;>10.1111/j.2042-7158.1998.tb06861.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9600719/&quot;>https://pubmed.ncbi.nlm.nih.gov/9600719</a></p></li><li><p>Rao, N, et al., &amp; Hwang, KK (1997). Comparative absorption of bismuth in Sprague-Dawley rats following oral administration of preparations containing bismuth sucrose octasulfate, bismuth subsalicylate, and bismuth subcitrate. <i>Biopharmaceutics &amp; drug disposition</i> 18(1) 1–8. DOI:<a href=&quot;https://doi.org/10.1002/(sici)1099-081x(199701)18:1&lt;1::aid-bdd996&gt;3.0.co;2-0&quot;>10.1002/(sici)1099-081x(199701)18:1&lt;1::aid-bdd996&gt;3.0.co;2-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9008264/&quot;>https://pubmed.ncbi.nlm.nih.gov/9008264</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A02BX05;
